The Parkinson’s Foundation has announced the expansion of PD GENEration: Mapping the Future of Parkinson’s Disease, a first-of-its-kind national initiative offering genetic testing and counseling for people with Parkinson’s disease (PD) at no cost.
Acorda Therapeutics Inc. submitted a New Drug Application to the U.S. Food and Drug Administration for Inbrija (CVT-301, levodopa inhalation powder). Acorda is developing Inbrija as a treatment for symptoms of OFF periods in people with Parkinson’s taking a carbidopa/levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms. The trade name for CVT-301, Inbrija, has been conditionally accepted by the FDA.
Reuters Health – Parkinson disease may have become more common over the past 30 years, at least according to a study in one Minnesota county. “This is the first evidence […]
Biogen plans to spin off hemophilia drug business into a public companyALS, Alzheimer's, Alzheimer's Disease, Alzheimer's Diseases, Amyotrophic Lateral Sclerosis (ALS), Analysts, Business, Health, Hemophilia, Hemophilia, Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Neurodegenerative Diseases, Neuropathic Pain, Neuropathic Pain, Neuroscience, Parkinson's, Parkinson's Disease, Parkinson's Disease, Restructuring, Spin-offs, Spinal Muscular Atrophy (SMA)
Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc’s drug for psychosis related to Parkinson’s disease. Nuplazid’s benefits outweighed the risks, the […]
2016 Annual Report: Top 10 Pipelines"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemia
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease. Recommendations for using the drug, which […]
Stanford University researchers are using the most sophisticated fly catcher in the world with the potential to speed up the rate of scientific insight into diseases like Alzheimer’s and Parkinson’s. […]
Could Body Posture During Sleep Affect How Your Brain Clears Waste? Stony Brook, NY – August 4, 2015 – Sleeping in the lateral, or side position, as compared to sleeping […]
Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders APL-130277, Sublingual Apomorphine, for On-Demand Treatment of OFF Episodes Associated with Parkinson’s Disease TORONTO, ONTARIO–(Marketwired – June 25, […]